Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IRIS International Reports Preliminary 2008 Results
For the fourth quarter, company expects to report GAAP diluted EPS of $0.18. Preliminary GAAP EPS results for the quarter and full year include approximately $0.05 related to
For the fourth quarter, company expects to report GAAP diluted EPS of $0.18. Preliminary GAAP EPS results for the quarter and full year include approximately $0.05 related to
From 1983 to 2007, Bryant held various worldwide commercial operations roles with Abbott Laboratories including: vice president of Abbott Vascular for Asia/Japan, vice president of Abbott Molecular Global
Leena Doshi, president of Doshi Diagnostic, said: “The Fonar Upright Multi-Position MRI is a perfect complement to existing closed high field and open low field magnets already in
According to SurgiQuest, its technology offers superior access during minimally invasive surgical procedures because it allows the surgeon to operate with an unprecedented degree of freedom. The AirSeal
Abbott has opened a new pharmaceutical analytical research laboratory in Singapore’s Biopolis research park. This new facility is Abbott’s first pharmaceutical research and development site in Southeast Asia.
The study was designed to elicit potential adverse effects from a single, very large dose of hGH-CTP, also known as MOD-4023. No adverse effects were observed, and the
Oscient filed this lawsuit under the Hatch-Waxman Act in response to the Paragraph IV certification notice received by the company from Lupin advising the company of the filing
In May 2008, the FDA approved the first Prochymal expanded access program for the treatment of pediatric graft versus host disease (GVHD) patients. Congress and the FDA created
The trials are planned to begin in medical centers in Israel and in the US as soon as local regulatory approvals and agreements with the medical centers are
To date, the company has enrolled more than 70 subjects and participating clinical sites will be permitted to enroll additional subjects until February 10, 2009. This randomized trial